A plain language summary of the CEPHEUS study: D-VRd for newly diagnosed multiple myeloma patients who are not expected to receive a stem cell transplant
The CEPHEUS study evaluated the effectiveness of adding daratumumab to the standard VRd regimen (bortezomib, lenalidomide, and dexamethasone)…